404 related articles for article (PubMed ID: 19464901)
41. Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.
Kim CY; Mahaney PE; McConnell O; Zhang Y; Manas E; Ho DM; Deecher DC; Trybulski EJ
Bioorg Med Chem Lett; 2009 Sep; 19(17):5029-32. PubMed ID: 19632110
[TBL] [Abstract][Full Text] [Related]
42. Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor.
Sabb AL; Vogel RL; Welmaker GS; Sabalski JE; Coupet J; Dunlop J; Rosenzweig-Lipson S; Harrison B
Bioorg Med Chem Lett; 2004 May; 14(10):2603-7. PubMed ID: 15109661
[TBL] [Abstract][Full Text] [Related]
43. APD-356 (Arena).
Jandacek RJ
Curr Opin Investig Drugs; 2005 Oct; 6(10):1051-6. PubMed ID: 16259227
[TBL] [Abstract][Full Text] [Related]
44. Improved lead-finding for kinase targets using high-throughput docking.
McInnes C
Curr Opin Drug Discov Devel; 2006 May; 9(3):339-47. PubMed ID: 16729730
[TBL] [Abstract][Full Text] [Related]
45. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening.
Pérez-Nueno VI; Pettersson S; Ritchie DW; Borrell JI; Teixidó J
J Chem Inf Model; 2009 Apr; 49(4):810-23. PubMed ID: 19358515
[TBL] [Abstract][Full Text] [Related]
46. Design of fructose-2,6-bisphosphatase inhibitors: a novel virtual screening approach.
Shaikh MS; Mittal A; Bharatam PV
J Mol Graph Model; 2008 Feb; 26(6):900-6. PubMed ID: 17644015
[TBL] [Abstract][Full Text] [Related]
47. 7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.
Fish PV; Brown AD; Evrard E; Roberts LR
Bioorg Med Chem Lett; 2009 Apr; 19(7):1871-5. PubMed ID: 19269173
[TBL] [Abstract][Full Text] [Related]
48. Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening.
Rastelli G; Degliesposti G; Del Rio A; Sgobba M
Chem Biol Drug Des; 2009 Mar; 73(3):283-6. PubMed ID: 19207463
[TBL] [Abstract][Full Text] [Related]
49. Discovery of 5-HT6 receptor ligands based on virtual HTS.
Tasler S; Kraus J; Wuzik A; Müller O; Aschenbrenner A; Cubero E; Pascual R; Quintana-Ruiz JR; Dordal A; Mercè R; Codony X
Bioorg Med Chem Lett; 2007 Nov; 17(22):6224-9. PubMed ID: 17892934
[TBL] [Abstract][Full Text] [Related]
50. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
51. Molecular modeling of the 3D structure of 5-HT(1A)R: discovery of novel 5-HT(1A)R agonists via dynamic pharmacophore-based virtual screening.
Xu L; Zhou S; Yu K; Gao B; Jiang H; Zhen X; Fu W
J Chem Inf Model; 2013 Dec; 53(12):3202-11. PubMed ID: 24245825
[TBL] [Abstract][Full Text] [Related]
52. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.
Kellenberger E; Springael JY; Parmentier M; Hachet-Haas M; Galzi JL; Rognan D
J Med Chem; 2007 Mar; 50(6):1294-303. PubMed ID: 17311371
[TBL] [Abstract][Full Text] [Related]
53. Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtual screening.
Renner S; Schneider G
J Med Chem; 2004 Sep; 47(19):4653-64. PubMed ID: 15341481
[TBL] [Abstract][Full Text] [Related]
54. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.
Kiss R; Kiss B; Könczöl A; Szalai F; Jelinek I; László V; Noszál B; Falus A; Keseru GM
J Med Chem; 2008 Jun; 51(11):3145-53. PubMed ID: 18459760
[TBL] [Abstract][Full Text] [Related]
55. Integrating structure- and ligand-based virtual screening: comparison of individual, parallel, and fused molecular docking and similarity search calculations on multiple targets.
Tan L; Geppert H; Sisay MT; Gütschow M; Bajorath J
ChemMedChem; 2008 Oct; 3(10):1566-71. PubMed ID: 18651695
[TBL] [Abstract][Full Text] [Related]
56. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening.
Klabunde T; Giegerich C; Evers A
J Med Chem; 2009 May; 52(9):2923-32. PubMed ID: 19374402
[TBL] [Abstract][Full Text] [Related]
57. A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor.
Clark DE; Higgs C; Wren SP; Dyke HJ; Wong M; Norman D; Lockey PM; Roach AG
J Med Chem; 2004 Jul; 47(16):3962-71. PubMed ID: 15267235
[TBL] [Abstract][Full Text] [Related]
58. Combining pharmacophore fingerprints and PLS-discriminant analysis for virtual screening and SAR elucidation.
Askjaer S; Langgård M
J Chem Inf Model; 2008 Mar; 48(3):476-88. PubMed ID: 18281962
[TBL] [Abstract][Full Text] [Related]
59. Pharao: pharmacophore alignment and optimization.
Taminau J; Thijs G; De Winter H
J Mol Graph Model; 2008 Sep; 27(2):161-9. PubMed ID: 18485770
[TBL] [Abstract][Full Text] [Related]
60. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay.
Meng T; Su HR; Binkert C; Fischli W; Zhou L; Shen JK; Wang MW
Acta Pharmacol Sin; 2008 Apr; 29(4):517-27. PubMed ID: 18358099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
